Trial · NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960, Phase 1, Phase 2, Recruiting, AbbVie
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM). Trials, record NCT06953960. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06953960
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- NCT number
- NCT06953960
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 325 participants, estimated
- Lead sponsor
- AbbVie
- Conditions
- Multiple Myeloma
- Interventions
- Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig
- First posted
- 2025-05-01
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-Limiting Toxicities (DLT)s of ABBV-453 | Up to Approximately 45 Months | DLT events are defined as specific clinically significant adverse events or abnormal laboratory values assessed as events regardless of attribution to ABBV-453, except those clearly and incontrovertibly associated with underlying disease or extraneous causes. |
| Primary | Number of Participants with Adverse Events (AE)s | Up to Approximately 4.5 Years | An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
| Secondary | Overall Response Rate (ORR) | Up to Approximately 4.5 Years | ORR is defined as the percentage of participants with a confirmed partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR) per Investigator review according to International Myeloma Working Group (IMWG) 2016 criteria. |
| Secondary | Progression-Free Survival (PFS) | Up to Approximately 4.5 Years | PFS is defined as time from first study treatment to the earliest documented disease progression according to IMWG 2016 criteria, as determined by the investigator, or death due to any cause, whichever occurs earlier. |
| Secondary | Duration of Response (DOR) | Up to Approximately 4.5 Years | DOR is defined as the time from the date of achieving the first confirmed sCR/CR/VGPR/PR to the date of recurrence, disease progression according to IMWG 2016 criteria, as determined by the investigator, or death of any cause, whichever occurs earlier. |
| Secondary | Time-to-Progression (TTP) | Up to Approximately 4.5 Years | TTP will be defined as the number of days from the date of first dose to the date of earliest disease progression. |
| Secondary | Time to Next Treatment | Up to Approximately 4.5 Years | Time to next treatment will be defined as the number of days from the date of first dose to the date of next treatment. |
| Secondary | Minimal Residual Disease (MRD) Negativity | Up to Approximately 4.5 Years | MRD negativity is defined as having less than 1 myeloma cell that may remain in the bone marrow aspirate per 10\^5 nucleated cells. Rate of MRD negativity will be determined. |
| Secondary | Overall Survival (OS) | Up to Approximately 4.5 Years | OS is defined as time from first study treatment to death due to any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06953960
GET https://conductscience.org/api/trials/v1/NCT06953960/registered